Small Bone Innovations Deutschland GmbH (SBi Deutschland), a orthopedic company, has appointed Dirk Dembski as international marketing director, Gudrun Klein as product manager for Germany, and Vincent Friso as international foot & ankle product specialist. Dembski has over ten years of management and marketing experience and is responsible for managing SBi Deutschland and international marketing.
SBi has also appointed Florian Kemmerich as president of Small Bone Innovations International, S.A.S., which is based in Bourg-en-Bresse, France. He is responsible for international sales and for developing new international markets. Kemmerich has extensive experience in the orthopedics markets in Europe, the US and Latin America.
Before joining SBi, Kemmerich was managing director of B. Braun Melsungen AG and vice president, sales, Latin America for another B. Braun company, Aesculap, AG & Co. KG. Kemmerich speaks five languages.
Viscogliosi said: “Florian Kemmerich’s addition to our executive management team highlights the growing importance of our international business and enhances SBi’s ability to realize the emerging opportunity in international markets.”
Before joining SBi Deutschland, he worked in business development at the German organization of one of the world’s largest orthopedic companies. He will report directly to Kemmerich.
Klein has over 25 years of healthcare experience including more than ten years in medical device sales. In her new role, she is responsible for product marketing in Germany and will report to Dembski.
Friso will lead driving international sales of the S.T.A.R. system as well as the rest of SBi’s extensive lower limb product portfolio. Friso has been promoted internally from his prior role as a direct sales representative for SBi in France.
Kemmerich said: “Germany is one of the largest SB&J markets in Europe and an important market for the S.T.A.R. ankle, our three-piece, mobile-bearing, uncemented ankle prosthesis. With the infrastructure and team now in place, we are well positioned to take advantage of the opportunity in this key SB&J market.”